AzTrials
AzTrials

Intracranial HemorrhagesNCT06525727

Validation of Falls Decision Rule to Exclude Intracranial Bleeding in Geriatric Fall Patients

An observational study of Intracranial Hemorrhages, run by Marmara University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Although falls are the most important cause of intracranial hemorrhage in the population over 65, studies have shown that bleeding occurs in only 5% of geriatric patients who fall. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Intracranial Hemorrhages
What is being tested?
Falls Decision Rule
How many people
800 participants
Where
1 siteTurkey (Türkiye)
Study dates
20 Jan 2024to 12 Nov 2024
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Study population: The study population consists of geriatric patients aged 65 years and older who present to the emergency department within 48 hours of experiencing a fall on level ground ((either inside or outside), off a chair, toilet seat, or out of bed). These patients will be included if they provide informed consent or if their legal guardians provide consent if the patients are unable to do so. The study aims to externally validate the Falls Decision Rule to exclude intracranial bleeding in this specific population. All patients meeting the inclusion criteria and none of the exclusion criteria will be enrolled in the study, and they will be observed for clinically significant intracranial bleeding for up to 42 days post-fall.

Who may be able to join

  • Patients aged 65 years and older.
  • Patients who presented to the emergency department within 48 hours of a fall.
  • Patients who provided informed consent to participate in the study or whose legal guardians provided consent if the patients are unable to do so.

Who cannot join

  • Patients who have already been included in the study previously.
  • Patients who refuse medical treatment or withdraw consent during the study period.
  • Patients with incomplete data necessary for the study.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Marmara University Pendik Training and Research Hospital

    Istanbul, Pendik

Other trials in Turkey (Türkiye)

About this study

Official title: External Validation of the Falls Decision Rule to Exclude Intracranial Bleeding Without Head CT in Geriatric Patients Presenting to the Emergency Department With A Fall

Although falls are the most important cause of intracranial hemorrhage in the population over 65, studies have shown that bleeding occurs in only 5% of geriatric patients who fall. Guidelines have been developed to assist the clinician in identifying patients at risk of intracranial hemorrhage due to the relatively low incidence but significant morbidity and mortality. The 'Falls Decision Rule' was developed by de Wit et al. in 2023 to assess the need for CT in this patient group. In this study, external validation of this newly developed score was planned to evaluate its safety, applicability, and authenticity.

Read the detailed description

In the geriatric population (≥65 years), falls are responsible for 70% of traumatic brain injury. Computed tomography (CT) evaluation of the brain used in evaluating these patients makes it possible to detect intracranial hemorrhage in the early period. Thus, it plays a critical role in initiating timely and necessary interventions. These interventions include blood pressure control, hemorrhage control, and neurosurgical interventions.

Although the most important cause of intracranial hemorrhage in this population is falls, studies have shown that bleeding occurs in only 5% of geriatric patients who fall. Therefore, it is inefficient and costly to perform brain CT evaluation in every patient.

Rules have been developed to assist the clinician in identifying patients at risk of intracranial hemorrhage, which has a relatively low incidence but significant morbidity and mortality. The Canadian Brain CT rule, one of the most widely used rules for this purpose, determines the need for brain CT in patients with head trauma. However, this rule applies to patients with disorientation, amnesia, or loss of consciousness. There are insufficient studies to guide neuroimaging for older adults who hit their heads while falling but do not experience these symptoms. In addition, guidance from the literature for older adults who fall but cannot describe what happened or did not hit their heads is also insufficient. The 'Falls Decision Rule' was developed by de Wit et al. in 2023 to assess the need for CT in this patient group. This criterion was developed by including a total of 4308 patients in the United States and Canadian emergency departments. It suggests that in patients in the geriatric population, there is no need for Brain CT in the absence of significant head trauma due to falls, no memory loss due to falls, no newly developing neurological examination disorder, and a clinical frailty score of less than 5. The sensitivity of this score to exclude clinically significant bleeding is 98.6% (95% CI 94.9-99.6), and the negative predictive value is 99.8% (95% CI 99.2-99.8).

This newly developed rule was developed only in a specific geographical region. In this study, external validation of this newly developed score was planned in order to evaluate its safety, applicability, and accuracy.

Patients over 65 years of age who come to the emergency department with a fall will be observationally recorded on the case form after obtaining consent from the patient or his/her relatives and will be followed up for clinically significant intracranial hemorrhage within 42 days. This study is a validation study, and the protocol used in the original study will be followed. The study is a prospective observational study. The study will start after ethics committee approval and will be conducted at Marmara University Pendik Training and Research Hospital. The data collection process will be completed when the targeted sample size is reached.

The sample size was calculated for the diagnostic value study planned to validate the fall decision rule developed by de Wit et al. to rule out patients with intracranial hemorrhage. Using the incidence, sensitivity, and specificity values shared by the authors as a reference, the minimum sample size to be included in the study was calculated as 663, with 80% power and 0.05% margin of error. Considering the risk of missing and inaccurate measurements, the target sample size was increased by 15% and set as 763.

Data will be obtained from patient files, Hospital Information Management System, and PACS systems; Demographic information (age, gender), Known diseases (HT, DM, AF, CHF, etc.), Information on falls, Physical examination information), Consultation notes, if any, Antiplatelet, anticoagulant use, Frailty score, The CT scan results will be saved.

Patients will be followed up for delayed intracranial hemorrhage within 42 days after the fall as in the original study. Also as in the methodology of the original study, patients will be followed up through the electronic information system. Previous studies have shown that this method has a low sensitivity (37%, 95% CI 21-56) for intracranial hemorrhage when patients are questioned for intracranial hemorrhage by telephone call. Therefore, in the original study and this study, it was planned to follow up the information of the patients from the electronic information system records instead of telephoning. The intracranial hemorrhage status of the patients within 42 days will be followed up through the hospital information system and patient information system.

Being tested
Falls Decision Rule
Keywords
Falls Rule, geriatric, rule, external validation
Medical subject headings
Intracranial Hemorrhages

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Falls Decision RuleOther

    The Falls Decision Rule is a rule used to assess the risk of intracranial haemorrhage in geriatric patients and to prevent brain tomography (CT) in low-risk patients. This rule recommends that brain CT is not necessary in patients who do not have significant head trauma, memory loss, newly developing neurological examination disorder, or frailty score lower than 5 after a fall.

Study groups in NCT06525727
Study groupRoleWhat they receive
Patients aged 65 years and overPatients aged 65 years and over who came to the emergency department with a fall on level ground ((either inside or outside), off a chair, toilet seat or out of bed) within the last 48 hours
Receives: Other: Falls Decision Rule

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With the Clinically Important Intracranial Bleeding

    The primary outcome is 'clinically significant intracranial hemorrhage' identified within 42 days following the initial presentation in the emergency department. 'Clinically significant intracranial hemorrhage' is defined as hemorrhage within the cranial vault, encompassing subdural, intracerebral, intraventricular, subarachnoid, epidural hemorrhage, and cerebral contusion, necessitating medical or surgical intervention. Medical intervention is defined as any of the following actions: temporary or permanent cessation of anticoagulant or antiplatelet medications; administration of an antifibrinolytic agent; reversal of anticoagulation; or hospitalization for neurological monitoring. These criteria align with those established in the original study.

    Measured: From baseline to 42 days (Patients will be followed up for 42 days after the fall and evaluated for delayed intracranial haemorrhage).

Secondary outcomes (2)
  1. Number of Participant With Neurosurgical Intervention

    Neurosurgical intervention was defined as any surgical procedure performed to manage clinically important intracranial bleeding (CIIB) identified either at the initial emergency department visit or during the 42-day follow-up period.

    Measured: 42 day

  2. Number of Patients With Mortality

    Mortality was defined as death occurring at any point during the 42-day follow-up period, regardless of whether it was directly attributed to clinically important intracranial bleeding (CIIB). Deaths were identified through national healthcare system.

    Measured: 42 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2024
  2. Study start20 Jan 2024
  3. Primary completion1 Oct 2024
  4. Study completion12 Nov 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
800 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06525727
Sponsor's protocol ID
12.01.2024.48
Status last verified
Jan 2026
First submitted
24 Jul 2024
Last updated
22 Jan 2026
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Gray I, de Wit K. Fast-tracking falls - expediting emergency care with evidence. CJEM. 2025 Aug;27(8):580-581. doi: 10.1007/s43678-025-00970-x. No abstract available.

    PubMed 40856903
  • Kudu E, Altun M, Danis F, Karacabey S, Sanri E, Denizbasi A. Validating the falls decision rule: optimizing head CT use in older adults with ground-level falls. CJEM. 2025 Aug;27(8):629-637. doi: 10.1007/s43678-025-00937-y. Epub 2025 May 13.

    PubMed 40360963

Questions about this trial

What is this clinical trial studying?

An observational study of Intracranial Hemorrhages, run by Marmara University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Jul 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With the Clinically Important Intracranial Bleeding (time frame: From baseline to 42 days (Patients will be followed up for 42 days after the fall and evaluated for delayed intracranial haemorrhage).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06525727, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in